<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03777124</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-II-214</org_study_id>
    <nct_id>NCT03777124</nct_id>
  </id_info>
  <brief_title>Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and
      safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with
      KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Progression-Free Survival (PFS) as Assessed by the Independent Review Committee Using RECIST v1.1</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee Using RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>Time Frame: Baseline until PD or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Survival (OS)</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>Baseline until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>The proportion of patients who have achieved complete response， partial response and Stable disease assessed by investigators according to Recist v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response （DoR）</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>Duration of response （DoR）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>up to approximately 40 months</time_frame>
    <description>All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>NSCLC Stage IV</condition>
  <condition>KRAS Gene Mutation</condition>
  <condition>PD-1 Antibody</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>SHR-1210 +apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>Subjects receive SHR-1210 intravenous every 2 weeks</description>
    <arm_group_label>SHR-1210 +apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Subjects receive Apatinib orally every day</description>
    <arm_group_label>SHR-1210 +apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Subjects receive Pemetrexed intravenous every 3 weeks</description>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>subjects receive carboplatin intravenous every 3 weeks</description>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with histopathological diagnosis of adenocarcinoma non-small cell lung cancer
             (NSCLC) and clinical stage IV

          2. has not received prior systemic treatment for metastatic NSCLC.

          3. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Status

          4. confirmes by the central laboratory as KRAS gene mutation

          5. Has archived Tumor tissue samples

          6. Subject must have a measurable target lesion based on RECIST v1.1 .

          7. Women of childbearing age must undergo a serological pregnancy test within 3 days
             before the first dose with negative results. Female subjects of reproductive age and
             male subjects whose spouse is a woman of reproductive age must agree to effective
             contraception within 180 days after the study period and the last dose of the study
             drug.

          8. Subjects should be voluntarily participate in clinical studies and informed consent
             should be signed.

        Exclusion Criteria:

          1. active brain metastases and meningeal metastasis

          2. uncontrollable tumor-related pain

          3. massive pleural effusion, peritoneal effusion or pericardial effusion which cannot be
             controlled by repeated drainage;

          4. radiotherapy to lung that is &gt;30 Gy within 24 weeks before the first dose,

          5. imaging (CT or MRI) showed that the tumor invading the large vessels

          6. Known EGFR/ALK mutation.

          7. subjects with any known or suspected autoimmune diseases

          8. subjects with known or suspected interstitial pneumonia;

          9. Subjects with severe cardiovascular and cerebrovascular diseases

         10. arteriovenous thrombosis events, such as deep vein thrombosis and pulmonary embolism,
             occurred within 3 months;

         11. female subjects who are pregnant or lactation or who plan to be pregnant during the
             study period;

         12. positive HIV test;

         13. active hepatitis B

         14. evidence of active TB infection within 1 year before first dose;

         15. severe infection occurred within 4 weeks before the first dose

         16. patients with clinically significant bleeding symptoms or with obvious bleeding
             tendency in the first month

         17. subjects who is on systemic immunogenic agents;

         18. a history of severe allergic reactions to other monoclonal antibodies/fusion proteins;

         19. History of severe allergic reactions to carboplatin or pemetrexed or their preventive
             drugs;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>KRAS mutant</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianjun Zou, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu HengRui Medicine Co., Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shun Lu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiaotong University,Shanghai chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Zou, MD, PhD</last_name>
    <phone>021-60453139</phone>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ChengLei qiao, PM</last_name>
    <email>qiaochenglei@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

